October 18, 2023
Company Description: We are a biotech company that has been developing new drugs by focusing on the protein degrader field since 2016/2017. About 50 people are working together in Korea, the United States, and through the CRO (20 FTEs). IPO plan: 2025 H1 (Korean stock market, Kosdaq) Strong discovery platform capability: - PinE3_Novel E3 Ligase ligand discovery capability - Ligase2 Program_Novel E3 ligase ligand that potentially works with any target protein (mostly, focused on oncology) - PinGLUE_Molecular Glue Degrader discovery capability Programs: - CK1a-Selective Molecular Glue Degrader (Preclinical) - Blood & Solid tumor - Discovery program: 7 programs
Korea, Republic of
CEO/Top Company Official
Lead Product in Development
Two own platform technologies. One of lead pipeline is under pre-clinical strage.
Development Phase of Primary Product